Göran Landberg (Former)
81 – 90 of 119
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
(
- Contribution to journal › Article
-
Mark
A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells.
(
- Contribution to journal › Article
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation.
(
- Contribution to journal › Article
-
Mark
Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
(
- Contribution to journal › Article
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Hypoxia-induced dedifferentiation of tumor cells - A mechanism behind heterogeneity and aggressiveness of solid tumors.
(
- Contribution to journal › Scientific review
-
Mark
Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.
(
- Contribution to journal › Article
-
Mark
Microarray-based Analyses of Hypoxia-induced Transcriptional Changes in Breast Cancer Cell Lines
(
- Contribution to journal › Article